IDH2R140Q-IN-2

CAS No. 2749568-16-7

IDH2R140Q-IN-2( —— )

Catalog No. M37247 CAS No. 2749568-16-7

IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 922 In Stock
10MG 1121 In Stock
25MG 1501 In Stock
50MG 1841 In Stock
100MG 2325 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    IDH2R140Q-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.
  • Description
    IDH2R140Q-IN-2 (compound 36) is an an orally active IDH2R140Q inhibitor (IC50: 29 nM). IDH2R140Q-IN-2 reduces D2HG production in TF-1 cell lines expressing mutant IDH2R140Q (IC50: 10 nM). IDH2R140Q-IN-2 suppresses D2HG levels in tumor tissue. IDH2R140Q-IN-2 can be used for research of acute myeloid leukemia (AML).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    Dehydrogenase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2749568-16-7
  • Formula Weight
    484.4
  • Molecular Formula
    C21H18F6N6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    FC(F)(F)C=1C=CC=C(C1)NC=2N=C(N=C(N2)N3CCC(O)C3)NC4=CC=CC(=C4)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wei Q, et al. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced hERG Inhibitory Activity for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2023 Sep 28;66(18):12894-12910.?
molnova catalog
related products
  • LDH-IN-1

    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.?LDH-IN-1 inhibits the growth of MiaPaCa2 pancreatic cancer and A673 sarcoma cells with IC50s of 2.23 and 1.21 μM).

  • Succinyl phosphonate...

    Succinyl phosphonate trisodium salt is an inhibitor of α-ketoglutarate dehydrogenase (KGDHC).

  • Tenuifoliside C

    Tenuifoliside C isolated from polygala tenuifolia willd is a target lactate dehydrogenase inhibitor. It significantly inhibits chlorzoxazone 6-hydroxylation catalyzed by CYP2E1.